乳腺癌肿瘤代谢异质性与p53基因表达和淋巴结转移相关性的研究
|
摘要
目的:分析乳腺癌肿瘤代谢异质性与p53基因表达和乳腺癌淋巴结转移的关系。方法:选取接受~(18)F-FDG PET/CT检查的原发性乳腺癌患者34例,分别测定每例患者原发灶的肿瘤代谢异质因子(heterogeneity factor,HF),同时将HF与p53基因表达和淋巴结转移进行相关性分析,采用受试者工作特性曲线(area under receiver operating characteristic curve,ROC)分析HF对p53基因突变及淋巴结转移的诊断效能。结果:HF与乳腺癌p53基因表达呈弱相关性(P <0. 05); HF与淋巴结转移无相关性(P> 0. 05)。结论:HF与乳腺癌p53基因表达具有相关性,HF对预测p53基因表达具有一定意义,然而,HF不能预测乳腺癌是否有淋巴结转移。
Objective: To evaluate the relationship between tumor heterogeneity factor and p53 and study the correlation of tumor heterogeneity factor and lymph node metastasis. Methods: Thirty four patients with primary breast cancer who underwent PET-CT examination were selected. The HF value of each patient was calculated by a computer. We analyzed the correlation between HF and p53 and studied HF and lymph node metastasis respectively. Results: There was a significant positive correlation between HF and p53 in breast cancer( P < 0. 05). However,HF was not associated with lymph node metastasis( P > 0. 05). Conclusion: HF is associated with p53 in breast cancer. So,computing HF helps the prediction of p53. HF can provide reference for tumor diagnosis,prognosis estimation and clinical guidance. However,HF cannot predict whether breast cancer patients have lymph node metastasis.
Objective: To evaluate the relationship between tumor heterogeneity factor and p53 and study the correlation of tumor heterogeneity factor and lymph node metastasis. Methods: Thirty four patients with primary breast cancer who underwent PET-CT examination were selected. The HF value of each patient was calculated by a computer. We analyzed the correlation between HF and p53 and studied HF and lymph node metastasis respectively. Results: There was a significant positive correlation between HF and p53 in breast cancer( P < 0. 05). However,HF was not associated with lymph node metastasis( P > 0. 05). Conclusion: HF is associated with p53 in breast cancer. So,computing HF helps the prediction of p53. HF can provide reference for tumor diagnosis,prognosis estimation and clinical guidance. However,HF cannot predict whether breast cancer patients have lymph node metastasis.
引文
[1]Ueda S,Tsuda H,Asakawa H,et al.Clinicopathological and prognostic relevance of uptake level using18F-fluorodeoxy glucose positron emission tomography/computed tomography fusion imaging(18F-FDG PET/CT)in primary breast cancer[J].Jpn J Clin Oncol,2008,38(4):250-258.
[2]Oshida M,Uno K,Suzuki M,et al.Predicting the prognoses of breast carcinoma patients with positron emission tomography using2-deoxy-2-fluoro[18F]-D-glucose[J].Cancer,2015,82(11):2227-2234.
[3]Inoue T,Yutani K,Taguchi T,et al.Preoperative evaluation of prognosis in breast cancer patients by[(18)F]2-deoxy-2-fluoroD-glucose-positron emission tomography[J].J Cancer Res Clin Oncol,2004,130(5):273-278.
[4]YAN SC,JIAO X,LI Y,et al.Clinical significance of Ki67 in p53Mutation-positive breast cancer[J].Modern Oncology,2014,22(2):310-313.[闫顺朝,焦昕,李悦,等.p53突变型乳腺癌中Ki67表达水平的临床意义[J].现代肿瘤医学,2014,22(2):310-313.]
[5]ZHANG LL,MA L,GENG CZ,et al.Correlation between extranodal invasion in axillary lymph node metastasis and prognosis of breast cancer patients[J].Chin J Pathol,2017,46(8):525-529.[张玲玲,马力,耿翠芝,等.腋窝淋巴结结外侵犯与乳腺癌患者预后的关系[J].中华病理学杂志,2017,46(8):525-529.]
[6]Miller TR,Grigsby PW.Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy[J].Int J Radiat Oncol Biol Phys,2002,53(2):353-359.
[7]Soret M,Bacharach SL,Buvat I.Partial-volume effect in PETtumor imaging[J].J Nucl Med,2007,48(6):932-945.
[8]Kim DH,Jung JH,Son SH,et al.Prognostic significance of intratumoral metabolic heterogeneity on18F-FDG PET/CT in pathological N0non-small cell lung cancer[J].Clin Nucl Med,2015,40(9):708-714.
[9]Hoey T.Drug resistance,epigenetics,and tumor cell heterogeneity[J].Sci Transl Med,2010,2(28):28ps19.
[10]Maley CC,Galipeau PC,Finley JC,et al.Genetic clonal diversity predicts progression to esophageal adenocarcinoma[J].Nature Genetics,2006,38(4):468-477.
[11]N Mcgranahan,C Swanton.Biological and therapeutic impact of intratumor heterogeneity in cancer evolution[J].J Cancer Cell,2015,27(1):15-26.
[12]Polyak K.Heterogeneity in breast cancer[J].J Journal of Clinical Investigation,2011,121(10):3786-3788.
[13]Son SH,Kim DH,Hong CM,et al.Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast[J].BMC Cancer,2014,14(1):585.
[14]Kim BS,Pak K,Yi KI,et al.Prognostic value of tumoral heterogeneity and volumetric parameters as measured by18F-FDG PET/CT in sinonasal cancer[J].European Archives of Oto-rhinoLaryngology,2016,274(3):1-7.
[15]Seol YM,Jang JY,Park K,et al.326P tumor heterogeneity in18F-FDG PET/CT as a biomarker for prediction of treatment response and locoregional recurrence in patients with pharyngeal cancer treated with chemoradiotherapy[J].Annals of Oncology,2015,26(9):96-97.
[16]Vousden KH,Lu X.Live or let die:The cell's response to p53[J].Nat Rev Cancer,2002,2(8):594-604.
[17]Casey G,Lo-Hsue M,Lopez ME,et al.Growth suppression of human breast cancer cells by the introduction of a wild-type p53gene[J].Oncogene,1991,6(10):1791-1797.
[18]Berns EM,Foekens JA,Vossen R,et al.Complete sequencing of tp53 predicts poor response to systemic therapy of advanced breast cancer[J].Cancer Reserach,2010,60(8):2155-2162.
[19]Seunghyeon Shin,Kyoung Pak.tumour heterogeneity assessed by18F-FDG PET/CT is not significantly associated with nodal metastasis in breast cancer[J].Oncology Research and Treatment,2016,39:62-66.
[20]A Smeets,A Ryckx.Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer[J].Springerplus,2013,2(1):1-7.
[21]Seung Hyun Son,Do-Hoon Kim.Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast[J].Bmc Cancer,2014,14(1):1-11.
[2]Oshida M,Uno K,Suzuki M,et al.Predicting the prognoses of breast carcinoma patients with positron emission tomography using2-deoxy-2-fluoro[18F]-D-glucose[J].Cancer,2015,82(11):2227-2234.
[3]Inoue T,Yutani K,Taguchi T,et al.Preoperative evaluation of prognosis in breast cancer patients by[(18)F]2-deoxy-2-fluoroD-glucose-positron emission tomography[J].J Cancer Res Clin Oncol,2004,130(5):273-278.
[4]YAN SC,JIAO X,LI Y,et al.Clinical significance of Ki67 in p53Mutation-positive breast cancer[J].Modern Oncology,2014,22(2):310-313.[闫顺朝,焦昕,李悦,等.p53突变型乳腺癌中Ki67表达水平的临床意义[J].现代肿瘤医学,2014,22(2):310-313.]
[5]ZHANG LL,MA L,GENG CZ,et al.Correlation between extranodal invasion in axillary lymph node metastasis and prognosis of breast cancer patients[J].Chin J Pathol,2017,46(8):525-529.[张玲玲,马力,耿翠芝,等.腋窝淋巴结结外侵犯与乳腺癌患者预后的关系[J].中华病理学杂志,2017,46(8):525-529.]
[6]Miller TR,Grigsby PW.Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy[J].Int J Radiat Oncol Biol Phys,2002,53(2):353-359.
[7]Soret M,Bacharach SL,Buvat I.Partial-volume effect in PETtumor imaging[J].J Nucl Med,2007,48(6):932-945.
[8]Kim DH,Jung JH,Son SH,et al.Prognostic significance of intratumoral metabolic heterogeneity on18F-FDG PET/CT in pathological N0non-small cell lung cancer[J].Clin Nucl Med,2015,40(9):708-714.
[9]Hoey T.Drug resistance,epigenetics,and tumor cell heterogeneity[J].Sci Transl Med,2010,2(28):28ps19.
[10]Maley CC,Galipeau PC,Finley JC,et al.Genetic clonal diversity predicts progression to esophageal adenocarcinoma[J].Nature Genetics,2006,38(4):468-477.
[11]N Mcgranahan,C Swanton.Biological and therapeutic impact of intratumor heterogeneity in cancer evolution[J].J Cancer Cell,2015,27(1):15-26.
[12]Polyak K.Heterogeneity in breast cancer[J].J Journal of Clinical Investigation,2011,121(10):3786-3788.
[13]Son SH,Kim DH,Hong CM,et al.Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast[J].BMC Cancer,2014,14(1):585.
[14]Kim BS,Pak K,Yi KI,et al.Prognostic value of tumoral heterogeneity and volumetric parameters as measured by18F-FDG PET/CT in sinonasal cancer[J].European Archives of Oto-rhinoLaryngology,2016,274(3):1-7.
[15]Seol YM,Jang JY,Park K,et al.326P tumor heterogeneity in18F-FDG PET/CT as a biomarker for prediction of treatment response and locoregional recurrence in patients with pharyngeal cancer treated with chemoradiotherapy[J].Annals of Oncology,2015,26(9):96-97.
[16]Vousden KH,Lu X.Live or let die:The cell's response to p53[J].Nat Rev Cancer,2002,2(8):594-604.
[17]Casey G,Lo-Hsue M,Lopez ME,et al.Growth suppression of human breast cancer cells by the introduction of a wild-type p53gene[J].Oncogene,1991,6(10):1791-1797.
[18]Berns EM,Foekens JA,Vossen R,et al.Complete sequencing of tp53 predicts poor response to systemic therapy of advanced breast cancer[J].Cancer Reserach,2010,60(8):2155-2162.
[19]Seunghyeon Shin,Kyoung Pak.tumour heterogeneity assessed by18F-FDG PET/CT is not significantly associated with nodal metastasis in breast cancer[J].Oncology Research and Treatment,2016,39:62-66.
[20]A Smeets,A Ryckx.Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer[J].Springerplus,2013,2(1):1-7.
[21]Seung Hyun Son,Do-Hoon Kim.Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast[J].Bmc Cancer,2014,14(1):1-11.